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reduce systemic spread of early stage lung cancer. In vivo experiments 
to explore this are currently being designed and will be presented.
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An increasing in energy consumption or hypoxia will lead to an en-
hanced production and releasing of adenosine in the tissues or cells. It 
is reasonable to assume, therefore, that metabolically active tumor cells 
may be characterized by a pronounced adenosine release. The local 
release of adenosine may then regulate the growth and development 
of these tumor cells in adenosine receptor-dependent and independent 
ways. Consequently, the presence of deﬁned receptor subtypes will 
be an important determinant for a speciﬁc effect of adenosine on the 
function of a tumor cell. The knowledge of the expression pattern 
of different tumor cells is essential for the development of potential 
therapeutic targets that may aid in more efﬁcient tumor growth control. 
Recently we have identiﬁed the expression proﬁle, signal transduction, 
molecular function and cell growth modulation of adenosine recep-
tor subtypes in the human breast cancer cell lines. To investigate the 
possible roles of adenosine receptors in other types of human cancers, 
in this study, we characterized the expression proﬁle of adenosine 
receptors in the human lung carcinoma cell line (Calu-6). Our purpose 
is to test the hypothesis that diverse human cancer cell lines, accord-
ing to their adenosine receptor subclass status, would show differential 
growth modulation and that this will help tumor growth inhibition. 
RNA was extracted and reverse transcribed to cDNA. PCR primers 
were synthesized from human adenosine receptor cDNA sequences. 
PCR was performed under optimized condition for each receptor 
subtype. Ampliﬁcation of a-actin mRNA served as control for RT-PCR. 
The PCR products were separated on 1.7% agarose gels. Preliminary 
RT-PCR results revealed expression of the adenosine A1, A2A and 
A2B receptors but no expression for A3 subtypes in the human lung 
carcinoma cell line. Further work(s) will be required to understand the 
functional roles of expressed adenosine receptors in the human lung 
cancer cells growth and development.
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We have treated with geﬁtinib for 27 recurrent lung cancer patients who 
underwent surgery at Nagoya City University Hospital. EGFR mutation 
status, copy number and protein expression were evaluated. This study 
included 22 adenocarcinomas and 14 non-smokers.EGFR mutations at 
kinase domain were found from 15 patients. EGFR mutant patients had 
signiﬁcantly better prognosis than patients without EGFR mutations 
(log-rank test, p=0.0039). Non-smoker (p=0.0042) and adenocarcinoma 
patients (p=0.0017) had signiﬁcantly better prognosis. However, gender 
(p=0.0874) and geﬁtinib response (p=0.2779) did not correlated with 
survival. Using the Cox hazard model, EGFR mutation (p=0.0221) 
and smoking status (p=0.0232) were independent prognostic factors. 
FISH analysis were also done for lung cancer tissues at surgery. The 
survival after geﬁtinib therapy was not different between FISH positive 
(4 copy>40% or 15 copy>10%) and FISH negative patients (Log-rank 
test, p=0.1911).EGFR protein expression was evaluated by immunohis-
tochemistry (IHC) using Dako Cytomation EGFR pharmDx Kit.IHC 
results signiﬁcantly correlated with FISH results (p=0.03). However, 
IHC results did not correlated with prognosis after geﬁtinib therapy 
(p=0.9029).
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Background: Synchrotron based Fourier Transform Infrared (FTIR) 
spectroscopy has the potential to become a useful tool to study biologi-
cal systems, in particular cancer [1]. Synchrotron radiation provides ex-
tremely high-ﬂux and bright electromagnetic light at energies ranging 
from the far-infrared to the hard x-ray regions. In the infrared region, 
its intrinsic high brightness allows to measure small areas down to 3 x 
3 µm. Therefore, chemical information regarding the composition and 
distribution of the main components of biological tissues, like proteins, 
lipids, and DNA, can be probed at subcellular level. We have studied 
the application of this technique as a tool helping in the pathological 
diagnosis of lung cancer, and the effects of chemotherapy drugs on lung 
cancer cells assessed at single cell level.
Methods: In vitro growing lung cancer cells where studied using 
synchrotron based FTIR spectroscopy at both at the CCLRC Dares-
bury synchrotron (U. K.) and at the European Synchrotron Radiation 
Facility (Grenoble, France). Lung cancer cells were directly grown on 
aluminium coated slides (lung cancer cells) and incubated overnight in 
the presence or absence of gemcitabine. IR spectra of air-dried or ﬁxed 
samples were obtained in the reﬂectance mode with scanning apertures 
ranging from 5 x 5 µm to 20 x 20 µm at a resolution of 4 cm-1 and co-
adding 256 scans. Parafﬁnised tissue samples from patients with lung 
cancer were placed on Low-e microscope slides (Kevley Technologies, 
USA) and studied in reﬂectance mode.
Results: The addition of gemcitabine to in vitro growing lung cancer 
cells induced changes in their FTIR spectra, at single cell level, in the 
amide I (CO groups) and amide II (NH groups). The peaks correspond-
ing to both areas shifted to lower wavenumbers, indicating cell death. 
The extent of the shifts correlated proportionally to tumour cell sensi-
tivity to gemcitabine. Regarding tumour diagnosis, synchrotron based 
spectroscopy could detect spectral changes between normal cells and 
tumour cells present in the same tissue sample.
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Conclusions: In conclusion, synchrotron based FTIR spectroscopy 
could become a tool to assess tumour cell sensitivity to chemotherapy 
agents, and to help pathologists in the diagnosis of cancer. We’ll dis-
cuss here its use as a screening tool to assess the effects of new drugs 
on cancer cells, and to characterise biomarkers of sensitivity of cancer 
cells to drugs. Also, we’ll discuss here its potential as a screening tool 
to assess the absence or presence of tumour cells in tissue samples 
based on spectral biomarkers.
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Introduction: Non-small cell lung cancer (NSCLC) is the most fre-
quent malignant disease of the respiratory system. Due to an insidious 
onset and early distant dissemination of NSCLC, results of treatment of 
even locally non-advanced stages of the disease are highly unsatisfac-
tory. Telomerase activity could be one of prognostic factors, not related 
to the clinical advancement of cancer. 
The Aim of the Study: Evaluation of the relationship between telom-
erase activity in transthoracic ﬁne-needle biopsy (TFNB) aspirates 
taken from peripheral NSCLC, cancer advancement, risk of death and 
survival free of cancer recurrence. 
Material and Methods: The study group consisted of 88 patients 
with peripheral inﬁltration of the lung. All of them had TFNB of the 
focal lesion performed. Aspirates were subjected to standard cytologi-
cal evaluation. Additionally, telomerase activity in the specimens was 
determined with the PCR-ELISAPLUS method. NSCLC advancement 
was assessed according to the WHO criteria. The manner of cancer 
treatment and patient survival were assessed. 
Results: NSCLC was newly diagnosed in 79 subjects: 20 patients 
(25.3%) with stage I, 15 (19.0%) with stage II, 22 (27.85%) with stage 
III, and 22 (27.85%) with stage IV. In 9 cases, a benign lesion of the 
lung parenchyma was recognized. An increased telomerase activity was 
observed in 10 (50%) patients with stage I, in 8 (53%) patients with 
stage II, in 16 (73%) patients with stage III and 22 (100%) patients 
with stage IV. Nobody with benign inﬁltration had a detectable level 
of telomerase. It was revealed (log-linear analysis) that the higher 
telomerase activity in primary tumor, the more probable non-operable 
NSCLC and cancer metastases to distant organs. An increased telom-
erase activity in TFNB aspirates was related to 7 times higher relative 
risk of death during the study [RR = 6.9 (CI: 1.8-26.8); p < 0.05]. 
NSCLC recurrence after radical treatment appeared only in 1 (6.2%) 
case without an increased telomerase activity in comparison to 6 (20%) 
cases with a detectable telomerase level [RR = 2.5 (CI: 0.3-19.3); p < 
0.05]. Telomerase activity in aspirates derived from TFNB of peripher-
al NSCLC could be a helpful independent signiﬁcant prognostic factor 
of lung cancer advancement and risk of death or cancer recurrence.
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Background: TARSH (Target of NESH-SH3) is a presumptive signal 
transduction molecule interacting with NESH which is implicated to 
have some roles in lung cancer metastasis. We have previously found 
evidence for TARSH being predominantly expressed in the mouse lung 
and being induced during cellular senescence of mouse embryonic 
ﬁbroblasts. On the basis of relationship between cellular senescence 
and carcinogenesis, we analyzed TARSH mRNA expression in human 
primary lung cancer.
Methods: Fifteen human lung cancer cell lines and 80 clinical cancer 
specimens were analyzed in this study. Both neoplastic and non-neo-
plastic tissue samples were obtained from patients who underwent sur-
gery for primary lung cancer: 58 for adenocarcinoma including 10 of 
bronchioloalveolar carcinoma (BAC), 17 for squamous cell carcinoma, 
and 5 for the others (including 3 of large cell carcinoma and 2 of small 
cell carcinoma). Total RNA was extracted from each sample, followed 
by quantitative real-time reverse transcription PCR with SYBR Green. 
The expression level of TARSH in each sample was normalized with 
respect to that of GAPDH. We then deﬁned T/N ratio as the ratio of the 
average mRNA expression levels for each clinical cancer specimen to 
that of corresponding non-neoplastic lung tissue.
Results: On the Northern hybridization analysis, TARSH was strongly 
expressed in the human normal lung. In 15 human lung cancer cell lines 
tested, TARSH expression was completely lost or remarkably down-
regulated as demonstrated by quantitative real-time RT-PCR. We found 
that TARSH expression level was reduced in all cancer specimens 
when compared with the non-neoplastic lung tissue obtained from the 
same patient. The T/N ratio in adenocarcinoma, squamous cell carci-
noma and the others was 0.126 (in a range from 0.003 to 0.832), 0.011 
(from 0.001 to 0.035) and 0.072 (from 0.001 to 0.231) respectively. In 
particular, BAC showed relatively higher T/N ratio than others. There 
was some correlation between TARSH expression and clinicopatho-
logical characteristics when applied multi-parametric analysis.
Conclusions: The expression of TARSH mRNA was remarkably 
downregulated in all lung cancer cell lines examined, and signiﬁcantly 
low in all (80 cases) of the lung cancer specimens when compared to 
the expression in corresponding non-neoplastic lung tissue specimens. 
The cancer-associated transcriptional inactivation of TARSH suggests 
that TARSH could be used as a biomarker for lung cancer development.
